{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05878951",
            "orgStudyIdInfo": {
                "id": "STU00218130"
            },
            "organization": {
                "fullName": "Northwestern University",
                "class": "OTHER"
            },
            "briefTitle": "Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms",
            "officialTitle": "A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms",
            "therapeuticArea": [
                "Rare Diseases",
                "Other"
            ],
            "study": "examining-the-effects-of-intra-detrusor-botox-at-time-of-holep-in-men-with-overactive-bladder-symptoms"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08-24",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-04",
            "studyFirstSubmitQcDate": "2023-05-24",
            "studyFirstPostDateStruct": {
                "date": "2023-05-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Amy Krambeck",
                "investigatorTitle": "Professor of Urology",
                "investigatorAffiliation": "Northwestern University"
            },
            "leadSponsor": {
                "name": "Northwestern University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "University of Calgary",
                    "class": "OTHER"
                },
                {
                    "name": "Ohio State University",
                    "class": "OTHER"
                },
                {
                    "name": "University of Alberta",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",
            "detailedDescription": "Patients with significant preoperative urgency and/or urge urinary incontinence (UUI) along with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) may require post-HoLEP anticholinergic, B-3 agonist, or intravesical OnabotulinumtoxinA administration. This injection is a guideline recommended for treatment in patients with severe irritative LUTS (urgency, UUI) and overactive bladder."
        },
        "conditionsModule": {
            "conditions": [
                "Urinary Incontinence",
                "Overactive Bladder Syndrome",
                "Overactive Bladder",
                "Urologic Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intra-detrusor OnabotulinumtoxinA Injection",
                    "type": "EXPERIMENTAL",
                    "description": "Injection of intra-detrusor OnabotulinumtoxinA into the bladder will be performed.",
                    "interventionNames": [
                        "Drug: OnabotulinumtoxinA"
                    ]
                },
                {
                    "label": "No intra-detrusor OnabotulinumtoxinA Injection",
                    "type": "NO_INTERVENTION",
                    "description": "Injection of intra-detrusor OnabotulinumtoxinA into the bladder will not be performed."
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "OnabotulinumtoxinA",
                    "description": "Intra-detrusor OnabotulinumtoxinA is commonly known as botox",
                    "armGroupLabels": [
                        "Intra-detrusor OnabotulinumtoxinA Injection"
                    ],
                    "otherNames": [
                        "Botox"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Improve Overactive Bladder Symptoms (OAB) utilizing botox injections into the bladder.",
                    "description": "Examine the safety and effect of intra-detrusor botulinum toxin injections at the time of helium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Difference in safety/ adverse effects",
                    "description": "Identifying changes in post-op urinary retention, gross hematuria, UTI, ED visits and any additional complications.",
                    "timeFrame": "90 days"
                },
                {
                    "measure": "Difference in patient REDCap surveys (gross hematuria dysuria, incontinence)",
                    "description": "Identifying symptom resolution at different time points (1 month, 3 months, 6 months)",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Difference in efficacy endpoints (3-month clinic/telephone follow-up)",
                    "description": "Identifying efficacy endpoints as they relate to the use of anti-cholinergics, incontinence survey, post void residuals, continence pads requirements if any.",
                    "timeFrame": "3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Component of OAB symptoms including frequency, nocturia, urgency, and/or urge related incontinence\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to OnabotulinumtoxinA injections\n* Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy\n* Patients who lack decisional capacity\n* Active urinary tract infection",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Men experiencing overactive bladder symptoms",
            "minimumAge": "18 Years",
            "maximumAge": "89 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alyssa McDonald",
                    "role": "CONTACT",
                    "phone": "312-695-8146",
                    "email": "Alyssa.McDonald@northwestern.edu"
                },
                {
                    "name": "Allaa Fadl-Alla",
                    "role": "CONTACT",
                    "phone": "312-695-8146",
                    "email": "Allaa.Fadlalla@northwestern.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Amy Krambeck, MD",
                    "affiliation": "Northwestern University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Northwestern Medicine",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alyssa McDonald",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014549",
                    "term": "Urinary Incontinence"
                },
                {
                    "id": "D000053201",
                    "term": "Urinary Bladder, Overactive"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014555",
                    "term": "Urination Disorders"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000059411",
                    "term": "Lower Urinary Tract Symptoms"
                },
                {
                    "id": "D000020924",
                    "term": "Urological Manifestations"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M17299",
                    "name": "Urinary Incontinence",
                    "asFound": "Urinary Incontinence",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7936",
                    "name": "Enuresis",
                    "relevance": "LOW"
                },
                {
                    "id": "M27167",
                    "name": "Urinary Bladder, Overactive",
                    "asFound": "Overactive Bladder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "asFound": "Urologic Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17305",
                    "name": "Urination Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M29464",
                    "name": "Lower Urinary Tract Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "M22659",
                    "name": "Urological Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019274",
                    "term": "Botulinum Toxins, Type A"
                },
                {
                    "id": "C000542869",
                    "term": "abobotulinumtoxinA"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009465",
                    "term": "Neuromuscular Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065087",
                    "term": "Acetylcholine Release Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21257",
                    "name": "Botulinum Toxins, Type A",
                    "asFound": "Overnight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M250193",
                    "name": "abobotulinumtoxinA",
                    "asFound": "Overnight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5183",
                    "name": "Botulinum Toxins",
                    "relevance": "LOW"
                },
                {
                    "id": "M3473",
                    "name": "Acetylcholine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                }
            ]
        }
    },
    "hasResults": false
}